中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.017 seconds)

    Soluble and immunoreactive variants of HTLV capsid antigen P24
    1.
    发明授权
    Soluble and immunoreactive variants of HTLV capsid antigen P24 有权

    公开(公告)号：US11567079B2

    公开(公告)日：2023-01-31

    申请号：US16577175

    申请日：2019-09-20

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Elke Faatz ,  Christian Scholz ,  Peter Muench

    IPC: C07K14/005 ,  C07K14/15 ,  G01N33/569

    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.

    METHOD FOR SEROLOGICAL DETECTION OF VIRAL ANTIGENS
    2.
    发明申请
    METHOD FOR SEROLOGICAL DETECTION OF VIRAL ANTIGENS 审中-公开

    公开(公告)号：US20190086412A1

    公开(公告)日：2019-03-21

    申请号：US16204580

    申请日：2018-11-29

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Ralf Bollhagen ,  Barbara Upmeier ,  Toralf Zarnt ,  Peter Muench ,  Manfred Ginter

    IPC: G01N33/576 ,  G01N33/53

    Abstract: The present disclosure relates to a method for detecting a core polypeptide of a hepatitis C virus (HCV) in a sample from a subject involving (a) contacting said sample with a base and with a surfactant having a cationic detergent, and (b) detecting a core polypeptide of the HCV in the sample. The present invention further relates to a method for pre-processing a sample from a subject for detection of HCV, involving contacting the sample with a base and with a surfactant having a cationic detergent; and to a pre-processing reagent for detecting HCV in a sample, having a base and a surfactant including a cationic detergent, wherein the surfactant also has a nonionic detergent. Moreover, the present disclosure further relates to kits, uses, and devices related to the methods disclosed.

    SOLUBLE AND IMMUNOREACTIVE VARIANTS OF HTLV CAPSID ANTIGEN P24
    3.
    发明申请
    SOLUBLE AND IMMUNOREACTIVE VARIANTS OF HTLV CAPSID ANTIGEN P24 审中-公开

    公开(公告)号：US20200033342A1

    公开(公告)日：2020-01-30

    申请号：US16577175

    申请日：2019-09-20

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Elke Faatz ,  Christian Scholz ,  Peter Muench

    IPC: G01N33/569 ,  C07K14/005

    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.

    SOLUBLE AND IMMUNOREACTIVE VARIANTS OF HTLV CAPSID ANTIGEN P24
    7.
    发明申请
    SOLUBLE AND IMMUNOREACTIVE VARIANTS OF HTLV CAPSID ANTIGEN P24 审中-公开

    公开(公告)号：US20170184591A1

    公开(公告)日：2017-06-29

    申请号：US15246607

    申请日：2016-08-25

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Elke Faatz ,  Christian Scholz ,  Peter Muench

    IPC: G01N33/569 ,  C07K14/005

    CPC classification number: G01N33/56988 ,  C07K14/005 ,  C07K2319/35 ,  C12N2740/14022 ,  C12N2740/14031 ,  C12N2740/14051 ,  G01N33/56983 ,  G01N2333/15 ,  G01N2469/20

    Abstract: The invention concerns soluble and antigenic HTLV p24 variants that can be fused to chaperones and their use in diagnostic applications such as immunoassays for detecting antibodies against HTLV-I or HTLV-II in an isolated biological sample. In particular, the invention relates to a soluble HTLV-I or HTLV-II p24 antigen comprising either the N- or the C-terminal domain of p24 and lacking the other domain. Moreover, the invention covers recombinant DNA molecules encoding these HTLV-I and -II fusion antigens as well as their recombinant production using expression vectors and host cells transformed with such expression vectors. In addition, the invention focuses on compositions of these HTLV p24 antigens with HTLV gp21 antigen and on an immunoassay method for detection of HTLV antibodies using the antigens of the invention. Also the use of HTLV p24 antigens in an in vitro diagnostic assay as well as a reagent kit for detection of anti-HTLV-antibodies comprising said HTLV antigens is encompassed.

    SOLUBLE AND IMMUNOREACTIVE FLAVIVRAL NS1 POLYPEPTIDES
    10.
    发明申请
    SOLUBLE AND IMMUNOREACTIVE FLAVIVRAL NS1 POLYPEPTIDES 有权

    公开(公告)号：US20220220158A1

    公开(公告)日：2022-07-14

    申请号：US17705704

    申请日：2022-03-28

    Applicant: Roche Diagnostics Operations, Inc.

    Inventor： Elke Faatz ,  Alexander Riedel ,  Christian Scholz ,  Peter Muench ,  Gloria Tabares ,  Mario Gloeck ,  Silke Luebcke ,  Juliane Benz

    IPC: C07K14/18 ,  C12N7/00 ,  G01N33/569 ,  C07K14/005

    Abstract: The disclosure relates to a polypeptide suitable for detecting antibodies against a flavivirus in an isolated biological sample having a flavivirus NS1 wing domain specific amino acid sequence, wherein no amino acid sequences from the NS1 β-ladder domain of said flavivirus are present in the polypeptide. In an embodiment, the flavivirus is selected from Zika virus (ZIKV), West-Nile virus (WNV), Dengue virus types 1-4 (DENV1-4), tick-borne encephalitis virus (TBEV), yellow fever virus (YFV) and Japanese encephalitis virus (JEV). Also disclosed is a method for producing said flaviviral NS1 wing domain specific polypeptides, a method for detecting antibodies specific for a first flavivirus species, the use of said flaviviral NS1 wing domain specific polypeptides for detecting antibodies as well as a reagent kit for detecting said flavivirus antibodies that has a flavivirus NS1 wing domain polypeptide.

Patent Agency Ranking